Martin E Sanders
Io Therapeutics, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Martin E Sanders as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:47 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02991651 · Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCIo Therapeutics · terminated · Lung Cancer, Nonsmall Cell · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:47 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Clin Cancer Res · 2017263 citationsRCR 7.6
- Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.Ann Intern Med · 2000202 citationsRCR 5.5
- 147 citationsRCR 3.6
- TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.Clin Cancer Res · 2020136 citationsRCR 5.5
- Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.Rheumatology (Oxford) · 2007116 citationsRCR 2.7
- Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.Arthritis Rheum · 2009108 citationsRCR 3.2
- 107 citationsRCR 3.1
- Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.J Clin Oncol · 200891 citationsRCR 1.8
- 89 citationsRCR 2.9
- Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.Arthritis Rheum · 199381 citationsRCR 2.1